228 related articles for article (PubMed ID: 26663620)
1. 17-Hydroxyprogesterone caproate in triplet pregnancy: an individual patient data meta-analysis.
Combs CA; Schuit E; Caritis SN; Lim AC; Garite TJ; Maurel K; Rouse D; Thom E; Tita AT; Mol B;
BJOG; 2016 Apr; 123(5):682-90. PubMed ID: 26663620
[TBL] [Abstract][Full Text] [Related]
2. A randomised controlled double-blind clinical trial of 17-hydroxyprogesterone caproate for the prevention of preterm birth in twin gestation (PROGESTWIN): evidence for reduced neonatal morbidity.
Awwad J; Usta IM; Ghazeeri G; Yacoub N; Succar J; Hayek S; Saasouh W; Nassar AH
BJOG; 2015 Jan; 122(1):71-9. PubMed ID: 25163819
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of progestogens to improve perinatal outcome in twin pregnancies: an individual participant data meta-analysis.
Schuit E; Stock S; Rode L; Rouse DJ; Lim AC; Norman JE; Nassar AH; Serra V; Combs CA; Vayssiere C; Aboulghar MM; Wood S; Çetingöz E; Briery CM; Fonseca EB; Worda K; Tabor A; Thom EA; Caritis SN; Awwad J; Usta IM; Perales A; Meseguer J; Maurel K; Garite T; Aboulghar MA; Amin YM; Ross S; Cam C; Karateke A; Morrison JC; Magann EF; Nicolaides KH; Zuithoff NP; Groenwold RH; Moons KG; Kwee A; Mol BW;
BJOG; 2015 Jan; 122(1):27-37. PubMed ID: 25145491
[TBL] [Abstract][Full Text] [Related]
4. 17-hydroxyprogesterone caproate for preterm rupture of the membranes: a multicenter, randomized, double-blind, placebo-controlled trial.
Combs CA; Garite TJ; Maurel K; Abril D; Das A; Clewell W; Heyborne K; How H; Huang W; Lewis D; Lu G; Miller H; Nageotte M; Porreco R; Sheikh A; Tran L;
Am J Obstet Gynecol; 2015 Sep; 213(3):364.e1-12. PubMed ID: 25979614
[TBL] [Abstract][Full Text] [Related]
5. Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of efficacy and safety.
O'Brien JM; Lewis DF
Am J Obstet Gynecol; 2016 Jan; 214(1):45-56. PubMed ID: 26558340
[TBL] [Abstract][Full Text] [Related]
6. 17α-hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: a randomized controlled trial.
Lim AC; Schuit E; Bloemenkamp K; Bernardus RE; Duvekot JJ; Erwich JJHM; van Eyck J; Groenwold RHH; Hasaart THM; Hummel P; Kars MM; Kwee A; van Oirschot CM; van Pampus MG; Papatsonis D; Porath MM; Spaanderman ME; Willekes C; Wilpshaar J; Mol BWJ; Bruinse HW
Obstet Gynecol; 2011 Sep; 118(3):513-520. PubMed ID: 21860279
[TBL] [Abstract][Full Text] [Related]
7. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
Manuck TA; Esplin MS; Biggio J; Bukowski R; Parry S; Zhang H; Huang H; Varner MW; Andrews W; Saade G; Sadovsky Y; Reddy UM; Ilekis J;
Am J Obstet Gynecol; 2016 Mar; 214(3):376.e1-8. PubMed ID: 26692181
[TBL] [Abstract][Full Text] [Related]
8. Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial.
Lim AC; Bloemenkamp KW; Boer K; Duvekot JJ; Erwich JJ; Hasaart TH; Hummel P; Mol BW; Offermans JP; van Oirschot CM; Santema JG; Scheepers HC; Schöls WA; Vandenbussche FP; Wouters MG; Bruinse HW;
BMC Pregnancy Childbirth; 2007 Jun; 7():7. PubMed ID: 17578562
[TBL] [Abstract][Full Text] [Related]
9. Progestational agents to prevent preterm birth: a meta-analysis of randomized controlled trials.
Sanchez-Ramos L; Kaunitz AM; Delke I
Obstet Gynecol; 2005 Feb; 105(2):273-9. PubMed ID: 15684151
[TBL] [Abstract][Full Text] [Related]
10. Vaginal progesterone vs intramuscular 17-hydroxyprogesterone caproate for prevention of recurrent preterm birth: a randomized controlled trial.
Boelig RC; Schoen CN; Frey H; Gimovsky AC; Springel E; Backley S; Berghella V
Am J Obstet Gynecol; 2022 May; 226(5):722.e1-722.e12. PubMed ID: 35189093
[TBL] [Abstract][Full Text] [Related]
11. [The use of progestatives for the prevention of spontaneous preterm birth].
Azria E
J Gynecol Obstet Biol Reprod (Paris); 2016 Dec; 45(10):1280-1298. PubMed ID: 27776845
[TBL] [Abstract][Full Text] [Related]
12. Progestogens in singleton gestations with preterm prelabor rupture of membranes: a systematic review and metaanalysis of randomized controlled trials.
Quist-Nelson J; Parker P; Mokhtari N; Di Sarno R; Saccone G; Berghella V
Am J Obstet Gynecol; 2018 Oct; 219(4):346-355.e2. PubMed ID: 29614278
[TBL] [Abstract][Full Text] [Related]
13. Prevention of preterm birth in triplets using 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial.
Caritis SN; Rouse DJ; Peaceman AM; Sciscione A; Momirova V; Spong CY; Iams JD; Wapner RJ; Varner M; Carpenter M; Lo J; Thorp J; Mercer BM; Sorokin Y; Harper M; Ramin S; Anderson G;
Obstet Gynecol; 2009 Feb; 113(2 Pt 1):285-92. PubMed ID: 19155896
[TBL] [Abstract][Full Text] [Related]
14. Eligibility, Utilization, and Effectiveness of 17-Alpha Hydroxyprogesterone Caproate in a Statewide Population-Based Cohort of Medicaid Enrollees.
Wang X; Garcia SM; Kellom KS; Boelig RC; Matone M
Am J Perinatol; 2023 Dec; 40(16):1770-1780. PubMed ID: 34784617
[TBL] [Abstract][Full Text] [Related]
15. 17 alpha-hydroxyprogesterone caproate does not prolong pregnancy or reduce the rate of preterm birth in women at high risk for preterm delivery and a short cervix: a randomized controlled trial.
Winer N; Bretelle F; Senat MV; Bohec C; Deruelle P; Perrotin F; Connan L; Vayssière C; Langer B; Capelle M; Azimi S; Porcher R; Rozenberg P;
Am J Obstet Gynecol; 2015 Apr; 212(4):485.e1-485.e10. PubMed ID: 25448515
[TBL] [Abstract][Full Text] [Related]
16. Association of 17α-Hydroxyprogesterone Caproate and Risk of Infection.
Mainiero AD; Rouse DJ; Lopes V; Hughes BL
Obstet Gynecol; 2015 Jul; 126(1):103-8. PubMed ID: 26241262
[TBL] [Abstract][Full Text] [Related]
17. Progestogens for Maintenance Tocolysis in Women With a Short Cervix: A Randomized Controlled Trial.
Facchinetti F; Vergani P; Di Tommaso M; Marozio L; Acaia B; Vicini R; Pignatti L; Locatelli A; Spitaleri M; Benedetto C; Zaina B; DʼAmico R
Obstet Gynecol; 2017 Jul; 130(1):64-70. PubMed ID: 28594783
[TBL] [Abstract][Full Text] [Related]
18. 17-alpha hydroxyprogesterone caproate for preterm birth prevention: Where have we been, how did we get here, and where are we going?
Manuck TA
Semin Perinatol; 2017 Dec; 41(8):461-467. PubMed ID: 28947068
[TBL] [Abstract][Full Text] [Related]
19. Adherence rates and outcomes for 17-hydroxyprogesterone caproate use in women with a previous history of preterm birth.
Edwards AM; Lowry SA; Mikovich S; Forinash AB; Babbar S
Am J Obstet Gynecol MFM; 2020 Aug; 2(3):100166. PubMed ID: 33345885
[TBL] [Abstract][Full Text] [Related]
20. A systematic review and meta-analysis of randomized controlled trials comparing 17-alpha-hydroxyprogesterone caproate versus placebo for the prevention of recurrent preterm birth.
Fernandez-Macias R; Martinez-Portilla RJ; Cerrillos L; Figueras F; Palacio M
Int J Gynaecol Obstet; 2019 Nov; 147(2):156-164. PubMed ID: 31402445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
